Sort
15,273 grants matching “antimicrobial resistance”
The Role of Sigma Factor B in Staphylococcus aureus biofilm development
$184,000Alexander R Horswill · University Of Iowa · R21 · FY2009 · AI
Contribution of Campylobacter jejuni nuclease in Animal Models of Acute Infection
$183,973Gerald E. Duhamel · Cornell University · R21 · FY2011 · AI
Collaborative Research: IIBR: Innovation: Bioinformatics: Linking Chemical and Biological Space: Deep Learning and Experimentation for Property-Controlled Molecule Generation
$183,910Kevin P Minbiole · Villanova University · · FY2023 · BIO
DEVELOPING EFFECTIVEANTIMICROBIAL-ALTERNATIVE STRATEGIES TO CONTROL LIVESTOCK DISEASES ARE NATIONAL PRIORITIES AND VITAL TO PROTECTING FOOD SECURITY. OUR LONG-TERM GOAL IS TO PROMOTE SUSTAINABLE AND PROFITABLE LIVESTOCK PRODUCTION BY DEVELOPING A CONTEMPORARY BOVINE ANAPLASMOSIS VACCINE THAT IS COST-EFFECTIVE, SAFE, AND CAPABLE OF INDUCING LONG-LASTING BROAD PROTECTION AGAINST CLINICAL ANAPLASMOSIS, AN ENDEMIC TICK-BORNE BACTERIAL DISEASE THAT IS CONSERVATIVELY ESTIMATED TO COST THE U.S. CATTLE INDUSTRY $300 MILLION PER YEAR. TETRACYCLINE ANTIMICROBIALS ARE THE ONLY FDA-APPROVED DRUG TO TREAT ANAPLASMOSIS AND ARE COMMONLY ADMINISTERED DURING THE ENTIRE PASTURE SEASON. CONTINUOUS PROLONGED EXPOSURE TO A SINGLE DRUG-CLASS IS NOT A JUDICIOUS USE OF MEDICALLY-IMPORTANT ANTIMICROBIALS AND PROMOTES DEVELOPMENT OF ANTIMICROBIAL RESISTANCE. WE HYPOTHESIZE THAT DEVELOPING AN ANAPLASMOSIS VACCINE BASED ON REGIONALLY-REPRESENTATIVE ANAPLASMA MARGINALE(THE AGENT OF BOVINE ANAPLASMOSIS) ANTIGEN COMBINED WITH MODERN ADJUVANTS WILL PROVIDE BROAD PROTECTION AGAINST CLINICAL DISEASE IN VACCINATED CATTLE. THROUGH COOPERATION BETWEEN SCIENTISTS, IMMUNOLOGISTS, CLINICIANS, AND EPIDEMIOLOGISTS, WE WILL TEST THIS HYPOTHESIS BY: I) EVALUATINGA. MARGINALESTRAIN DIVERSITY; II) EVALUATING THE EFFICACY OF THE PROTOTYPE ANAPLASMOSIS VACCINE TO PROVIDE BROAD PROTECTION UPON INFECTION OF CATTLE WITH DIFFERENT STRAINS OFA. MARGINALE; AND, III) EVALUATING THE EFFICACY OF THE PROTOTYPE ANAPLASMOSIS VACCINE DELIVERED IN A SLOW-RELEASE IMPLANT (SINGLE IMMUNIZATION) VERSUS A TRADITIONAL NEEDLE IMMUNIZATION SERIES (MULTIPLE IMMUNIZATIONS). AS FURTHER PROOF-OF-CONCEPT, WE WILL TEST OUR VACCINE DESIGN CONCEPT IN TANZANIA, ANOTHER LARGE CATTLE-PRODUCTION COUNTRY ENDEMIC FOR ANAPLASMOSIS, WITH FIELD-CHALLENGED CATTLE UNDER NATURAL HIGH-STRESS CONDITIONS. SUCCESSFUL COMPLETION OF THIS PROPOSAL WILL DELIVER A PROTOTYPE BROADLY EFFICACIOUS ANAPLASMOSIS VACCINE.AN EFFICACIOUS BOVINE ANAPLASMOSIS VACCINE WILL: I) REDUCE ECONOMIC LOSSES ASSOCIATED WITH CLINICAL DISEASE, II) REDUCE EXPENSES RELATED TO FEEDING ANTIMICROBIAL-MEDICATED FEED PRODUCTS FOR EXTENDED TIME PERIODS, AND III) PROTECT THE THERAPEUTIC EFFICACY OF MEDICALLY-IMPORTANT ANTIMICROBIALS FOR FOOD SAFETY AND PUBLIC HEALTH.
$183,864Kansas State University · · FY2020 · National Institute of Food and Agriculture
INTERDICISPLINARY PROGRAM IN BACTERIAL PATHOGENESIS
$183,850University Of Washington · T32 · FY2004 · AI
Delivering drugs via bacterial secretion systems
$183,769Marcin S Filutowicz · University Of Wisconsin-Madison · R21 · FY2010 · AI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.
$183,766Julian G Hurdle · Texas A&M University Health Science Ctr · R01 · FY2024 · AI
New Phosphated Polymers Prevent Microbial Colonization
$183,750Andrew R Dentino · Marquette University · R01 · FY2007 · DE
Tuberculosis in diabetic guinea pigs
$183,750Randall J Basaraba · Colorado State University · R21 · FY2011 · AI
Creation of a Generalizable ED-based Antimicrobial Stewardship Program Using Electronic Health Record Clinical Decision Support
$183,735Rakesh D Mistry · University Of Colorado Denver · R21 · FY2019 · AI
Development of Staphylococcalcidal Human Peptides
$183,615William Maurice Shafer · Emory University · R01 · FY2007 · AI
Tricytotoxic T cells protect against intracellular infection in human skin
$183,600Samuel Jackson Balin · University Of California Los Angeles · K08 · FY2019 · AR
Mechanisms of cefiderocol resistance
$183,500Yohei Doi · University Of Pittsburgh At Pittsburgh · R21 · FY2021 · AI
Analysis of Protein Synthesis in Bacterial Persisters
$183,471David A Tirrell · California Institute Of Technology · R21 · FY2017 · AI
Microbiology of Stenotrophomonas maltophilia infection
$183,347De Paul University · R15 · FY2005 · AI
Regulation of Yersinia Type III Secretion by YopK
$183,277Melanie Marketon · Trustees Of Indiana University · R21 · FY2009 · AI
Molecular Analysis of Antibiotic Resistance in Neisseria gonorrhoeae
$183,178Robert A Nicholas · Univ Of North Carolina Chapel Hill · R21 · FY2018 · AI
CK22-008 Midwest Virtual Laboratory of Pathogen Transmission in Healthcare Settings (MVL-PATHS)
$183,028Majid Bani Yaghoub · University Of Missouri Kansas City · U01 · FY2023 · CK
Early agr Activation is a Key Pathogenic Signature in Persistent MRSA Bacteremia
$183,010Yan Q. Xiong · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R21 · FY2012 · AI
Novel Diagnostics to Improve Antimicrobial Stewardship for Acute Respiratory Tract Infections in Resource-Limited Settings
$182,963Gayani Tillekeratne · Duke University · K23 · FY2019 · AI
Desaturases and Acetylenases from Basidiomycete Fungi
$182,898Indiana Univ-Purdue Univ At Indianapolis · R15 · FY2004 · GM
A Novel Self-Renewing Heparin-Binding Anti-microbial Device Surface Coating
$182,820David W Grainger · University Of Utah · R21 · FY2011 · DK
HOST GENETIC VARIATION REGULATING SALMONELLA INVASION AND DISEASE SUSCEPTIBILITY
$182,778Dennis Chun-Yone Ko · Duke University · R01 · FY2015 · AI
Identification of the factors contributing to resistance of Group A Streptococcus to human group IIA secreted phospholipase A2
$182,763Natalia Korotkova · University Of Kentucky · R21 · FY2021 · AI
Sodium bioenergetics in Yersinia pestis
$182,750Claudia C Hase · Oregon State University · R21 · FY2009 · AI